Atherosclerosis is a chronic inflammatory disease of arteries and is the most common underlying cause of CVDs. Graphic abstractĬardiovascular disease (CVD) is the leading cause of death worldwide which result in ≈ 17.8 million deaths globally, and the crude prevalence of CVD was 485.6 million cases in 2017. Together, these data demonstrate the potential of ASA6 antibody in targeted therapy and noninvasive imaging for atherosclerosis. Moreover, we conjugated ASA6 antibody to NaNdF 4 nanoparticles for noninvasive imaging of atherosclerotic plaques by magnetic resonance (MR) and near-infrared window II (NIR-II) imaging. Transcriptome analysis reveals the anti-atherosclerosis effect of ASA6 is related to the regulation of fatty acid metabolism and inhibition of M1 macrophage polarization. The atherosclerotic lesion area of ApoE −/− mice administrated with ASA6 antibody was significantly reduced. Meanwhile, ASA6 can also inhibit the uptake of Ox-LDL into macrophage to reduce macrophage apoptosis. ASA6 can bind to oxidized LDL (Ox-LDL) and atherosclerotic plaques. Here, we screened a novel scFv antibody, named as ASA6, from phage-displayed human scFv library. The purpose of this study was to develop novel human single-chain variable fragment (scFv) antibody specific to OSEs to image and inhibit atherosclerosis.
Innate and adaptive immune responses to OSEs play an important role in atherosclerosis.
Oxidation-specific epitopes (OSEs) are rich in atherosclerotic plaques.